As clinicians eagerly await the results of cardiovascular (CV) outcomes studies of novel Lp(a) lowering agents in development, leading lipid experts at this year’s European Atherosclerosis Congress (24-27 May, Athens, Greece) focused on the importance of managing conventional risk factors in today’s patients with elevated Lp(a). Other highlights included the potential of an Lp(a)-adjusted polygenic […]
Act now to reduce cardiovascular (CV) risk in patients with elevated Lp(a), and don’t delay until results of Lp(a) lowering outcome trials are available. This was the key message from Professor Florian Kronenberg, from the Medical University of Innsbruck, Austria, in his wide ranging review of ongoing Lp(a) outcomes trials and the importance of addressing traditional CV risk factors including in primary prevention populations.
An Lp(a)-adjusted polygenic risk score (PRS) for atherosclerotic cardiovascular disease (ASCVD) may improve risk assessment for myocardial infarction (MI) when used alongside traditional risk factors.
Increased levels of unbound apo(a) which occur with muvalaplin treatment are not correlated with changes in biomarkers of cardiovascular or kidney disease. This is the main finding from a post hoc analysis of data from a Phase 2 trial of muvalaplin, an Lp(a) lowering agent in development that, in contrast to other Lp(a) targeting agents, […]
If novel Lp(a) lowering therapies are released at comparable annual costs to other siRNA therapies, they are likely to be cost-effective for secondary prevention of cardiovascular disease, a preliminary health technology assessment presented by Professor Zanfina Ademi from Monash University, Melbourne, Australia, has shown. However, prices would need to be much lower if novel therapies […]
There may be a little more ethnic variation in the relationship between Lp(a) level and atherosclerotic cardiovascular disease (ASCVD) risk than previously thought, according to an analysis of data from the HELIUS cohort of 24,780 adults of African Surinamese, Dutch, Ghanaian, Moroccan, South Asian Surinamese and Turkish ethnicity.
